EUVIMEDEUVIMED entdecken
Crossref

A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma

Alessandro Borghi iD, Lucilla D'Abundo, Cristian Bassi, Laura Lupini, Valentina Tagliatti, Pierantonia Zedde, Giovanni Lanza, Roberta Gafà, Massimo Negrini, Monica Corazza

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Alessandro Borghi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie Infettive, Università di Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Vulvar Lichen Sclerosus, MicroRNAs, Lichen Sclerosus et Atrophicus, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 7 Literaturangaben. Gefördert von: University of Ferrara.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

https://doi.org/10.1093/bjd/ljad024 Dear Editor, Biomarkers useful for the identification of patients at risk of developing vulvar squamous cell carcinoma (VSCC) on a vulvar lichen sclerosus (VLS) background could lead to relevant prognostic advantages. To date, the development of such biomarkers is an unmet medical need. Among potential biomarker molecules, microRNAs (miRNAs) have been gaining attention. Involvement of miRNAs in vulvar carcinogenesis has been addressed with some evidence.1–6 We aimed to investigate whether miRNA expression could be useful to predict the progression from VLS to VSCC. This study, which was approved by the University-Hospital of Ferrara institutional review board (identification code 452/2021/Oss/AOUFe), included two different groups of formalin-fixed paraffin-embedded (FFPE) histologically proven VLS specimens: (i) 10 VLS samples that did not evolve towards carcinoma from patients with a mean clinical follow-up of 6 years, defined as VLS free from cancer (VLSfc); (ii) 13 samples including either VLS in which an invasive VSCC was histologically diagnosed in a subsequent biopsy, obtained after the first histological diagnosis of lichen sclerosus (n = 2, LIC19 and LIC20), or 11 VLS samples in which an invasive VSCC was diagnosed in the same surgical specimen. Both these sample types were defined as VLS cancer-associated (VLSca).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vulvar Lichen SclerosusMicroRNAsLichen Sclerosus et AtrophicusCarcinoma, Squamous CellVulvar NeoplasmsFemaleHumans

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Dipartimento di Scienze Mediche, Sezione di Dermatologia e Malattie Infettive, Università di Ferrara, Ferrara, Italy.
  • Dipartimento di Medicina Traslazionale e Laboratorio per le Tecnologie delle Terapie Avanzate (LTTA), Università di Ferrara, Ferrara, Italy.
  • Department of Translational Medicine, University of Ferrara, Ferrara, Italy.
  • Anatomic Pathology Unit, University Hospital of Ferrara, Ferrara, Italy.

ORCID-Profile: Alessandro Borghi

Förderung

  • University of Ferrara

Zitieren

APA

Borghi, A., D'Abundo, L., Bassi, C., Lupini, L., Tagliatti, V., Zedde, P., Lanza, G., Gafà, R., Negrini, M., & Corazza, M. (2023). A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad024

Vancouver

Borghi A, D'Abundo L, Bassi C, Lupini L, Tagliatti V, Zedde P, et al. A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad024

BibTeX
@article{Borghi2023,
  author = {Borghi, Alessandro and D'Abundo, Lucilla and Bassi, Cristian and Lupini, Laura and Tagliatti, Valentina and Zedde, Pierantonia and Lanza, Giovanni and Gafà, Roberta and Negrini, Massimo and Corazza, Monica},
  title = {A microRNA signature to predict risk progression of vulvar lichen sclerosus to squamous cell carcinoma},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad024}
}
Kostenlos starten →